+ Watch LXRX
on My Watchlist
A biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.
Biopharma company that works on mouse genetics , localizes potential drug targets , and then attempts to make drugs specific for those targets. Completely speculative play. If LX4211 succeeds (phase IIb trial currently enroling; results available in 2012) then it would get partnered with big pharma. That being said, a similar drug from Astra Zeneca just got shot down by the FDA.I would peg their chance of success at 1 in 3. They do have 3 more in the pipeline , 2 for irritable bowel syndrone and one for rheumatoid arthritis.Chance of a further dilution before the end of the year ~ 100%chance of being partnered or bought out by big pharma for a successful drug ~ 25%If the pipeline falls through, chance of going to zero by late 2012~ 100% !!!!Worth a speculative flier, the underlying technology and methodology is completely sound.... Though not necessarily enough to ensure success!
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions